Journey Medical (DERM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with introductions of directors, legal counsel, COO, and independent auditors in attendance.
Agenda included accepting motions, collecting votes, and receiving a preliminary report from the Inspector of Elections.
Board and executive committee updates
Directors Lindsay A. Rosenwald, Claude Maraoui, Justin Smith, Miranda Toledano, Neil Herskowitz, and Michael Pearce were nominated for re-election to serve until the 2027 annual meeting.
Overview of voting outcomes
Quorum was confirmed with a majority of shares represented as of the record date.
All director nominees were elected and the appointment of KPMG as independent auditors for 2026 was ratified.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Journey Medical
- EMROSI drives rapid growth, with rising revenue, margins, and expanded market access.DERM
A.G.P.'s Annual Virtual Healthcare Conference20 May 2026 - Q1 2026 revenue up 21% to $16M, net loss narrows, and EMROSI/Emrosi® expands market access.DERM
Q1 202613 May 2026 - Emrosi® drives revenue growth as the leading oral rosacea therapy, with expanding market access.DERM
Investor presentation13 May 2026 - Election of six directors and auditor ratification headline the 2026 annual meeting agenda.DERM
Proxy filing1 May 2026 - Virtual meeting to elect directors, ratify auditor, and review governance and compensation.DERM
Proxy filing30 Apr 2026 - Emrosi™ drives revenue growth as a best-in-class rosacea therapy with rapid market adoption.DERM
Investor presentation30 Apr 2026 - EMROSI's launch drove 10% revenue growth, margin gains, and improved profitability in 2025.DERM
Q4 202525 Mar 2026 - Q2 revenue $14.9M, positive EBITDA, DFD-29 FDA review ongoing, but going concern risks remain.DERM
Q2 20241 Feb 2026 - FDA approves Emrosi for rosacea, launching in early 2025 with proven superiority to Oracea.DERM
FDA Announcement17 Jan 2026